BioPharm International-02-01-2013

Viral Vaccines

Development requirements and regulatory guidance for biosimilars and biobetters.

Boot Camp Business Guide

February 01, 2013

NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation.

Guest Editorial

February 01, 2013

Ever since Twitter launched in 2006 and Facebook became mainstream, most industries have sought ways to connect with their consumers through social media.

Shortages spur efforts to overhaul manufacturing oversight.

Features

February 01, 2013

Innovative products and a range of indications drive the therapeutic antibody market.

Features

February 01, 2013

A look at vaccine history, markets, manufacturing, and overcoming the scale-up dilemma.

Project: transfer a manual concentration/diafiltration process for siRNA production.

Perspectives on Outsourcing

February 01, 2013

Is the contract-only CMO an endangered species?

Features

February 01, 2013

Tony Hitchcock of Cobra Biologics discusses challenges posed by production of viral vectors for vaccines.

Eastern Europe is moving towards a goal of harmonized regulations.

Global Reports

February 01, 2013

India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.

Manufacturing Best Practices

February 01, 2013

Improvement strategy should be linked to business strategy.